Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function

Annals of Hematology

Volumn 93, Issue 9, 2014, Pages 1523-1529

  Castelli, Roberto ^a   Deliliers, Giorgio Lambertenghi ^b   Colombo, Riccardo ^a   Moreo, Guido ^a   Gallipoli, Paolo ^c   Pantaleo, Giuseppe ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b Fondazione Matarelli   (Italy)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Anemia; Biosimilar epoetin (Binocrit); Cognitive function; Erythroid stimulating agents (ESAs); Myelodysplastic syndromes (MDS); Quality of life (QOL)

Indexed keywords

BIOSIMILAR AGENT; HEMOGLOBIN; IRON CHELATING AGENT; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BONE MARROW; BRAIN FUNCTION; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME DELETION; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPLASIA; HYPERTENSION; IRON CHELATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MINI MENTAL STATE EXAMINATION; MONOSOMY; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VERY ELDERLY; Y CHROMOSOME;

AGED; AGED, 80 AND OVER; ANEMIA; BIOSIMILAR PHARMACEUTICALS; BRAIN; ERYTHROPOIETIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK;

EID: 84905573287     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2070-8     Document Type: Article

References (50)

1. Tefferi A, Vardiman JW(2009) Myelodysplastic syndromes. N Engl J Med 361:1872-1885
2. Castelli R, Cassin R, Cannavò A, Cugno M (2013) Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13:1-7
3. Wright RA, Pantaleo G (2013) Effort processes in achieving performance outcomes: interrelations among and roles of core constructs. Behav Brain Sci 36(6):705-706
4. Pantaleo G, Miron A, Frankowski S, Ferguson M. Effects of deterrence on intensity of group identification and efforts to protect group identity. Motivation & Emotion, Special Issue on Effort, 2014, in press; ISSN: 0146-7239 EISSN: 1573-6644.
5. Lamperti E, Pantaleo G, Finocchiaro CY, Silvani A, Botturi A, Gaviani P, Sarno L, Salmaggi A (2012) Recurrent brain tumor: the impact of illness on patient's life. Support Care Cancer 20:1327-1332
6. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352:536-538
7. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA (2012) Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res 2:136-147
8. Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31(suppl 3):S2-S6
9. Seiter K (2013) Myelodysplasia: new approaches. Curr Treat Options Oncol 14:156-169
10. Fenaux P, Ades L (2013) How we treat lower-risk myelodysplastic syndromes. Blood 23(121):4280-4286
11. Kelaidi C, Fenaux P (2010) Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. Expert Opin Biol Ther 10(4):605-614
12. Abraham I, Mac Donald K (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 11:819-840
13. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924 (Pubitemid 351397066)
14. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532-1542
15. Aapro M (2009) An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 14(suppl 1):1
16. Castelli R, Ferrari B, Cortelezzi A, Guariglia A (2010) Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 8:482-494
17. Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167-176 (Pubitemid 40260326)
18. Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM(2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204-209
19. Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P (2013) High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 92:633
20. Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S (2013) Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 122:2286-2288
21. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 3, CD007303
22. Haag-Weber M, Vetter A, Thyroff-Friesinger U (2009) Therapeutic equivalence, long term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72:380-e90
23. Kerkhofs L, Boschetti G, Lugini A, Stanculeanu DL, Palomo AG (2012) Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol 8:751-756
24. Abraham I, MacDonald K (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 5:819-840
25. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK (2012) Biosimilars: what clinicians should know. Blood 120:5111-5117
26. Greenberg PL, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis of myelodysplastic syndromes. Blood 89:2079-2088 (Pubitemid 27132124)
27. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 15(108):419-425 (Pubitemid 44061337)
28. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S (2011) What are RBC-transfusion-dependence and - independence? Leuk Res 35:8-11
29. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13-19
30. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psych Res 12:189-198
31. Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R (2011)Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leuk Res 35:1472-1476
32. Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA (2011) Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27(5):951-960
33. Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34:1430-1436
34. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, DiMaio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S (2010) Italian Society of Hematology clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 34:1576-1588
35. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613
36. Geissler RG, Ganser A (1998) Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. BioDrugs 10:97-109 (Pubitemid 28401686)
37. Groupe Francais des Myelodysplasies, Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513-519
38. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, Carella AM (2003) Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 122:269-271 (Pubitemid 36859613)
39. Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34(11):1430-1436
40. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, Musto P, Balleari E (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070-1074
41. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A (1995) Apoptosis in bonemarrow biopsy samples involving stromal and hemopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-275
42. Greenberg PL (1998) Apoptosis and its role in myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 22:1123-1136
43. Aapro M, Cornes P (2012) Diana Sun and Ivo Abraham comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 4:95-105
44. IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals. 2010
45. Hong CH, Falvey C, Harris TB, Simonsick EM, Satterfield S, Ferrucci L, Metti AL, Patel KV, Yaffe K (2013) Anemia and risk of dementia in older adults: findings from the Health ABC study. Neurology 81:528-533
46. ArtzAS (2008)Anemia and the frail elderly. Semin Hematol 45:261-266
47. Lucca U, Tehamanti M, Mosconi P et al (2008) Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the 'health and anemia study'. PLoS ONE 3:e1920
48. Denny SD, Kuchibhatla MN, Cohen HJ (2006) Impact of anemia on mortality, cognition and function in community-dwelling elderly. Am J Med 119:327-334
49. Hare GM(2004) Anaemia and the brain. Curr Opin Anaesthesiol 17:363-369
50. Merelli A, Czornyj L, Lazarowski A (2013) Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr Pharm Des 19:6791-6801